Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Scleromyxedema in an Adult Following Sinopharm Bbibp-Corv Vaccination: An Extremely Rare Phenomenon Publisher



Parsaei A1 ; Rezaei SS2 ; Rahmani A3 ; Masoumi M2 ; Dehghanbanadaki H4 ; Norouzi S2 ; Riyahi MM2 ; Tabaraii R2 ; Montazeri SMH5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Faculty of Medicine, Tehran University of Medical Science, Tehran, Iran
  2. 2. Department of Rheumatology, Clinical Research Development Center, Shahid Beheshti Hospital, Qom University of Medical Sciences, Qom, Iran
  3. 3. Institute of Endocrinology and Metabolism, Iran University of Medical Science, Tehran, Iran
  4. 4. Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Student Research Committee, School of Medicine, Qom University of Medical Sciences, Qom, Iran

Source: Journal of Scleroderma and Related Disorders Published:2023


Abstract

Introduction: The Sinopharm BBIBP-CorV vaccine produces a variety of cutaneous adverse effects. Scleromyxedema is a mucinous connective tissue disorder that causes skin thickness and sclerodermoid changes. According to our findings, this is the first case of scleromyxedema induced by the Sinopharm immunization. Case description: We discuss the case of a 75-year-old woman who acquired progressive thickening of the skin in her limbs and trunk after getting the Sinopharm vaccination. Examination, laboratory testing, and a biopsy were used to verify scleromyxedema diagnosis. Intravenous immunoglobulins, mycophenolate mofetil, and prednisolone were used in the treatment of the patient. The outcomes from the 4-month follow-up were reassuring. Conclusion: This study emphasizes the need of considering scleromyxedema as a connective tissue pathology in patients who have recently received Sinopharm vaccine and have similar cutaneous signs. © The Author(s) 2022.
Related Docs
1. Clinical Characteristics and Treatment Outcomes of Scleromyxedema: A 10-Year Retrospective Survey, Case Reports in Dermatology (2022)
2. Safety and Adverse Events Related to Inactivated Covid-19 Vaccines and Novavax; a Systematic Review, Archives of Academic Emergency Medicine (2022)
Experts (# of related papers)
View all Related Experts
Zahra Saffarian (1)
Maryam Daneshpajooh (1)